UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1617
    +0.0020 (+0.17%)
     
  • GBP/USD

    1.3828
    -0.0066 (-0.47%)
     
  • BTC-GBP

    34,843.20
    +269.23 (+0.78%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • DOW

    31,496.30
    +572.16 (+1.85%)
     
  • CRUDE OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD FUTURES

    1,698.20
    -2.50 (-0.15%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

$11.21 Billion Cell Line Development Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; By Product; Application; and Geography

Research and Markets
·4-min read

Dublin, Feb. 10, 2021 (GLOBE NEWSWIRE) -- The "Cell Line Development Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; By Product; Application; and Geography" report has been added to ResearchAndMarkets.com's offering.

Hybridomas Segment to Register Highest CAGR in Cell Line Development Market during 2020-2027

The market was valued at US$ 4,160.42 million in 2019 and is projected to reach US$ 11,219.87 million by 2027; it is expected to grow at a CAGR of 13.3% from 2020 to 2027

The global cell line development market, based on type, is segmented into primary cell line, hybridomas, continuous cell lines, and recombinant cell lines. The recombinant cell lines segment held the largest share of the market in 2019. This growth is ascribed to the increasing demand for recombinant cell lines in the production of therapeutic recombinant proteins. However, the hybridomas segment is estimated to register the highest CAGR during the forecast period. This growth is attributed to rising research and development activities for novel biologics.

Stable cell lines are widely used in a wide range application, including biologics production, drug screening, and gene functional studies. The COVID-19 pandemic led to disruptions in all phases of drug development, and it has compelled many pharmaceutical companies and clinical research organizations (CROs) to put their clinical studies on hold. The new government policies, stay-at-home orders, social distancing norms, and widespread anxiety are among the prime challenges faced by researchers conducting the ongoing studies.

The growth of the cell line development market is attributed to factors such as increasing adoption of regenerative medicines, rising prevalence of cancer in the world, and mounting investments in R&D by pharmaceutical and biotechnology companies. However, the risks associated with cell line contamination hinder the growth of this market.

Merck KGaA, Thermo Fisher Scientific Inc., Selexis SA (JSR Corporation), BioFactura, Inc., Corning Incorporated, Sartorius AG, Lonza, GENERAL ELECTRIC, LakePharma, Inc., and WuXiAppTec Group are among the leading companies operating in the global cell line development market.

Key Topics Covered:

1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation

2. Cell Line Development Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Cell Line Development - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert Opinion

5. Global Cell Line Development Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Increasing Adoption of Regenerative Medicines
5.1.2 Rising Prevalence of Cancer
5.1.3 Growing Investment in R&D by Pharmaceutical and Biotechnology Companies
5.2 Key Restraints
5.2.1 Risk Associated with Cell Line Contamination
5.3 Key Opportunity
5.3.1 Middle Income Countries Creating Development Opportunities
5.4 Future Trend
5.4.1 Consistent Research in Drug Discovery Activities
5.5 Impact Analysis

6. Cell Line Development Market - Global Analysis
6.1 Global Cell Line Development Market Revenue Forecast and Analysis
6.2 Global Cell Line Development Market, By Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
6.3.1 Merck KGaA
6.3.2 Thermo Fisher Scientific Inc.

7. Cell Line Development Market - Revenue and Forecasts to 2027 - Type
7.1 Overview
7.2 Global Cell Line Development Market, by Type, 2019 & 2027 (% Share)
7.3 Primary Cell Line
7.4 Hybridomas
7.5 Continuous Cell Lines
7.6 Recombinant Cell Line

8. Cell Line Development Market Analysis and Forecasts to 2027 - Product
8.1 Overview
8.2 Global Cell Line Development Market, by Product, 2019 & 2027 (% Share)
8.3 Equipment
8.4 Media and Reagent

9. Cell Line Development Market Analysis and Forecasts to 2027 - Application
9.1 Overview
9.2 Global Cell Line Development Market Share by Application 2019 & 2027 (%)
9.3 Drug Discovery
9.4 Bioproduction
9.5 Tissue Engineering

10. Cell Line Development Market Revenue and Forecast to 2027 - Geographical Analysis

11. Impact Of COVID-19 Pandemic on Global Cell Line Development Market
11.1 North America: Impact Assessment of COVID-19 Pandemic
11.2 Europe: Impact Assessment of COVID-19 Pandemic
11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Cell Line Development Market - Industry Landscape
12.1 Overview
12.2 Growth Strategies Done by the Companies in The Market, (%)
12.3 Organic Developments Done by The Companies in the Market
12.4 Inorganic Developments Done by The Companies in the Market

13. Cell Line Development Market- Key Company Profiles

  • Thermo Fisher Scientific Inc.

  • Merck KGaA

  • Selexis SA (JSR Corporation)

  • BioFactura, Inc.

  • Corning Incorporated

  • Sartorius AG

  • Lonza

  • GENERAL ELECTRIC

  • LakePharma, Inc.

  • WuXi AppTec Group

For more information about this report visit https://www.researchandmarkets.com/r/x8w3c3

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900